glucosamine sulfate 1500 mg daily 	ibuprofen 400 mg twice a day	pre-treatment pain intensity	9729	10069	Although there was no statistically significant difference between groups regarding pre-treatment pain intensity (4.66 ± 2.43 in the ibuprofen group vs. 4.71 ± 2.11in the glucosamine sulfate group, P value: 0.83), pain severity was significantly lower in the glucosamine sulfate treated group on all follow-up visits [Table 1 and Figure 1].
glucosamine sulfate 1500 mg daily 	ibuprofen 400 mg twice a day	pre-treatment pain intensity	9738	9941	there was no statistically significant difference between groups regarding pre-treatment pain intensity (4.66 ± 2.43 in the ibuprofen group vs. 4.71 ± 2.11in the glucosamine sulfate group, P value: 0.83)
glucosamine sulfate 1500 mg daily 	ibuprofen 400 mg twice a day	mandibular opening in temporomandibular joint (TMJ) disorders 90 days after starting treatment	1665	1816	Post treatment pain and mandibular opening showed significantly more improvement in the glucosamine treated patients (P < 0.0001 and 0.01 respectively)
glucosamine sulfate 1500 mg daily 	ibuprofen 400 mg twice a day	mandibular opening in temporomandibular joint (TMJ) disorders 60 days after starting treatment	1665	1816	Post treatment pain and mandibular opening showed significantly more improvement in the glucosamine treated patients (P < 0.0001 and 0.01 respectively)
glucosamine sulfate 1500 mg daily 	ibuprofen 400 mg twice a day	mandibular opening in temporomandibular joint (TMJ) disorders 90 days after starting treatment	1455	1817	Comparing with baseline measures, both groups had significantly improved post-treatment pain (P < 0.0001 for both groups) and mandibular opening (P value: 0.001 for glucosamine sulfate and 0.03 for ibuprofen). Post treatment pain and mandibular opening showed significantly more improvement in the glucosamine treated patients (P < 0.0001 and 0.01 respectively).
glucosamine sulfate 1500 mg daily 	ibuprofen 400 mg twice a day	Post treatment pain in temporomandibular joint (TMJ) disorders	1455	1817	Comparing with baseline measures, both groups had significantly improved post-treatment pain (P < 0.0001 for both groups) and mandibular opening (P value: 0.001 for glucosamine sulfate and 0.03 for ibuprofen). Post treatment pain and mandibular opening showed significantly more improvement in the glucosamine treated patients (P < 0.0001 and 0.01 respectively).
glucosamine sulfate 1500 mg daily 	ibuprofen 400 mg twice a day	Gastrointestinal adverse events	11095	11286	Gastrointestinal adverse events including dyspepsia, abdominal pain and nausea were reported by 16 (53%) of ibuprofen treated and 5 (16%) of glucosamine sulfate treated patients (P < 0.0001).
